Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a novel vitamin C product engineered to provide active vitamin C directly to the skin. Additionally, it is advancing organic-inorganic hybrid technology, which functions as a sophisticated drug delivery system. This system integrates bio-friendly minerals to ensure the targeted and efficient transport of active substances to specific sites, a capability also leveraged in its anticancer drug carrier innovations. The enterprise was established in 2000 and is headquartered in Seoul, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.